Effect of Imatinib Mesylate on Chronic Myelogenous Leukemia Hematopoietic Progenitor Cells

References

• Fialkow, P.J., Jacobson, R.J. and Papayannopoulou, T. (1977) "Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macro-phage", American Journal of Medicine, 63, 125–130.
   Google Scholar
• Rowley, J.D. (1973) "Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining", Nature, 243, 290–293.
   Google Scholar
• Daley, G.Q. and Baltimore, D. (1988) "Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein", Proceedings of the National Academy of Sciences of the USA, 85, 9312–9316.
   PubMed Web of Science ®Google Scholar
• Daley, G.Q., Van Etten, R.A. and Baltimore, D. (1990) "Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome". Science, 247, 824–830.
   PubMed Web of Science ®Google Scholar
• Pear, W.S., Miller, J.P., Xu, L., Pui, J.C., Soffer, B., Quackenbush, R.C., et al. (1998) "Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow", Blood, 92, 3780— 3792
   Google Scholar
• Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Druker, B.J., et al. (1996) "Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative", Cancer Research, 56, 100 — 104.
   Google Scholar
• Druker, B.J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G.M., Fanning, S., et al. (1996) "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells", Nature Medicine, 2, 561 — 566.
   Google Scholar
• Heinrich, MC., Griffith, D.J., Druker, B.J., Wait, C.L., Ott, K.A. and Zigler, A.J. (2000) "Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor", Blood, 96, 925–932.
   PubMed Web of Science ®Google Scholar
• Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N.B., et al. (1997) "CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins", Blood, 90, 4947 — 4952.
   Google Scholar
• le Coutre, P., Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., et al. (1999) "In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor", Journal of the National Cancer Institute, 91, 163–168.
   Google Scholar
• Deininger, M.W., Goldman, J.M., Lydon, N. and Melo, J.V. (1997) "The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells", Blood, 90, 3691–3698.
   PubMed Web of Science ®Google Scholar
• Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., et al. (2001) "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia", New England Journal of Medicine, 344, 1031–1037.
   Google Scholar
• Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., (2001) "Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome". New England Journal of Medicine, 344, 1038–1042.
   PubMed Web of Science ®Google Scholar
• O'Brien, S.G., Guilhot, F., Larson, R.A., Gathmann, I., Baccarani, M., Cervantes, F., et al. (2003) "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia", New England Journal of Medicine, 348, 994 — 1004.
   Google Scholar
• Marley, S.B., Deininger, M.W., Davidson, R.J., Goldman, J.M. and Gordon, M.Y. (2000) "The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplifica-tion of granulocyte- macrophage progenitors from patients with chronic myeloid leukemia", Experimental Hematology, 28, 551 — 557.
   Google Scholar
• Gordon, M.Y., Marley, S.B., Lewis, J.L., Davidson, R.J., Nguyen, DX., Grand, F.H., et al. (1998) "Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM", Journal of Clinical Investigation, 102, 710–715.
   Google Scholar
• Marley, S.B., Davidson, R.J., Lewis, J.L., Nguyen, DX., Eades, A., Parker, S., et al. (2001) "Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo", Leukaemia Research, 25, 997–1002.
   PubMed Web of Science ®Google Scholar
• Kasper, B., Fruehauf, S., Schiedlmeier, B., Buchdunger, E., Ho, A.D. and Zeller, W.J. (1999) "Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors", Cancer Chemotherapy Pharmacology, 44, 433–438.
   PubMed Web of Science ®Google Scholar
• Holtz, M.S., Slovak, ML., Zhang, F., Sawyers, C.L., Forman, S.J. and Bhatia, R. (2002) "Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leuke-mia through reversal of abnormally increased proliferation", Blood, 99, 3792–3800.
   PubMed Web of Science ®Google Scholar
• Graham, S.M., Jorgensen, H.G., Allan, E., Pearson, C., Alcorn, M.J., Richmond, L., et al. (2002) "Primitive, quiescent, Philadel-phia-positive stem cells from patients with chronic myeloid leukemia are insensitive to 5171 in vitro", Blood, 99, 319— 325.
   Google Scholar
• Horita, M., Andreu, E.J., Benito, A., Arbona, C., Sans, C., Benet, I., et al. (2000) "Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bc1-xL", Journal of Experimental Medicine, 191, 977— 984.
   Google Scholar
• Bhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D.S., Sawyers, C.L., et al. (2003) "Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment", Blood, 101, 4701 — 4707.
   Google Scholar
• Wolff, N.C. and Ilaria, R.L., Jr. (2001) "Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571", Blood, 98, 2808–2816.
   PubMed Web of Science ®Google Scholar
• Hochhaus, A., Kreil, S., Corbin, AS., La Rosee, P., Muller, M.C., Lahaye, T., et al. (2002) "Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy", Leukemia, 16, 2190 — 2196.
   Web of Science ®Google Scholar
• Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., et al. (2001) "Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification", Science, 293, 876–880.
   PubMed Web of Science ®Google Scholar
• Shah, N.P., Nicoll, J.M., Nagar, B., Gorre, M.E., Paquette, R.L., Kuriyan, J., et al. (2002) "Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia", Cancer Cell, 2, 117–125.
   PubMed Web of Science ®Google Scholar
• von Bubnoff, N., Schneller, F., Peschel, C. and Duyster, J. (2002) "BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to 5TI571: a prospec-tive study.[comment]", Lancet, 359, 487–491.
   PubMed Web of Science ®Google Scholar
• Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N., Lai, J.L., Philippe, N., Facon, T., et al. (2002) "Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment", Blood, 100, 1014–1018.
   PubMed Web of Science ®Google Scholar
• Campbell, L.J., Patsouris, C., Rayeroux, K.C., Somana, K., Januszewicz, E.H. and Szer, J. (2002) "BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration". Cancer Genetics and Cytogenetics, 139, 30 — 33.
   Google Scholar
• Uchida, N., Combs, J., Chen, S., Zanjani, E., Hoffman, R. and Tsukamoto, A. (1996) "Primitive human hematopoietic cells displaying differential efflux of the rhodamine 123 dye have distinct biological activities", Blood, 88, 1297–1305.
   PubMed Web of Science ®Google Scholar
• Goodell, MA., Brose, K., Paradis, G., Conner, AS. and Mulligan, R.C. (1996) "Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo", Journal of Experimental Medicine, 183, 1797–1806.
   Google Scholar
• Goodell, M.A., Rosenzweig, M., Kim, H., Marks, D.F., DeMaria, M., Paradis, G., et al. (1997) "Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species", Nature Medicine, 3, 1337 — 1345.
   Google Scholar
• Scharenberg, C.W., Harkey, M.A. and Torok-Storb, B. (2002) "The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic pro-genitors", Blood, 99, 507 — 512.
   Google Scholar
• Tipping, A.J., Mahon, F.X., Zafirides, G., Lagarde, V., Goldman, J.M. and Melo, J.V. (2002) "Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs", Leukemia, 16, 2349–2357.
   Google Scholar
• Thiesing, J.T., Ohno-Jones, S., Kolibaba, K.S. and Druker, B.J. (2000) "Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells", Blood, 96, 3195 — 3199.
   Google Scholar
• Scappini, B., Onida, F., Kantarjian, H.M., Dong, L., Verstovsek, S., Keating, M.J., et al. (2002) "In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells", Cancer, 94, 2653–2662.
   PubMed Web of Science ®Google Scholar
• Marley, S.B., Davidson, R.J., Goldman, J.M. and Gordon, M.Y. (2002) "Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia", British Journal of Haematology, 116, 162–165.
   Google Scholar
• La Rosee, P., Johnson, K., O'Dwyer, M.E. and Druker, B.J. (2002) "In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia", Experimental Hematology, 30, 729–737.
   PubMed Web of Science ®Google Scholar
• Hoover, R.R., Mahon, F.X., Melo, J.V. and Daley, G.Q. (2002) "Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336", Blood, 100, 1068–1071.
   PubMed Web of Science ®Google Scholar
• Klejman, A., Rushen, L., Morrione, A., Slupianek, A. and Skorski, T. (2002) "Phosphatidylinosito1-3 kinase inhibitors enhance the anti-leukemia effect of STI571", Oncogene, 21, 5868–5876.
   PubMed Web of Science ®Google Scholar
• Nimmanapalli, R., O'Bryan, E., Huang, M., Bali, P., Burnette, P.K., Loughran, T., et al. (2002) "Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin", Cancer Research, 62, 5761–5769.
   PubMed Web of Science ®Google Scholar
• La Rosee, P., Corbin, A.S., Stoffregen, E.P., Deininger, M.W. and Druker, B.J. (2002) "Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)", Cancer Re-search, 62, 7149–7153.
   PubMed Web of Science ®Google Scholar
• Huang, M., Dorsey, J.F., Epling-Burnette, P.K., Nimmanapalli, R., Landowski, T.H., Mora, L.B., et al. (2002) "Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells", Oncogene, 21, 8804–8816.
   PubMed Web of Science ®Google Scholar
• Wisniewski, D., Lambek, C.L., Liu, C., Strife, A., Veach, D.R., Nagar, B., et al. (2002) "Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases", Cancer Research, 62, 4244–4255.
   Google Scholar
• Kraker, A.J., Hartl, B.G., Amar, A.M., Barvian, M.R., Showalter, H.D. and Moore, C.W. (2000) "Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors", Biochemical Pharmacology, 60, 885–898.
   PubMed Web of Science ®Google Scholar